Mar 13, 2023 07:00AM
Mar 13, 2023 06:56AM
Feb 23, 2023 08:30AM
Feb 13, 2023 07:30AM
Feb 2, 2023 04:01PM
Jan 24, 2023 08:56AM
Jan 5, 2023 04:01PM Provention Bio Inc. (PRVB) Appoints Rita Jain to its Board
Jan 5, 2023 04:01PM
Nov 18, 2022 09:14AM
Nov 18, 2022 08:59AM
Nov 18, 2022 08:56AM
Nov 17, 2022 05:46PM
Nov 17, 2022 05:45PM
Nov 17, 2022 05:05PM FDA Approves Provention Bio's (PRVB) Drug That Can Delay Onset of Type 1 Diabetes
Nov 4, 2022 04:05PM
Nov 3, 2022 07:00AM
Oct 13, 2022 07:30AM
Oct 7, 2022 04:01PM
Oct 6, 2022 08:13AM
Oct 6, 2022 07:00AM
Sep 19, 2022 07:30AM Provention Bio Announces Senior Leadership Addition
Sep 6, 2022 04:01PM
Sep 2, 2022 04:01PM
Aug 31, 2022 06:12PM
Aug 4, 2022 07:00AM
Aug 2, 2022 04:05PM
Jul 28, 2022 07:30AM
Jul 7, 2022 07:28PM Provention Bio Announces $60 Million Private Placement
Jul 5, 2022 04:01PM
Jun 30, 2022 04:01PM
Jun 30, 2022 04:01PM
Jun 3, 2022 07:35AM
Jun 3, 2022 07:03AM
Jun 3, 2022 07:00AM
May 12, 2022 07:30AM Provention Bio to Host a May 19, 2022 Virtual Investor Event Focused on the Potential Commercial Launch of Teplizumab Later This Year
May 5, 2022 07:05AM
May 5, 2022 07:00AM
May 3, 2022 07:30AM
Apr 4, 2022 04:05PM
Mar 21, 2022 07:02AM
Mar 21, 2022 07:00AM
Mar 4, 2022 04:05PM Provention Bio Announces the Grant of Inducement Awards
Feb 24, 2022 07:00AM
Feb 22, 2022 07:33AM
Feb 22, 2022 07:30AM
Jan 28, 2022 09:21AM
Jan 27, 2022 04:05PM
Jan 27, 2022 04:05PM
Jan 20, 2022 04:05PM Provention Bio Announces Initiation of the Phase 2a PREVAIL-2 Study of PRV-3279 (CD32B × CD79 Bispecific DART® Molecule) in Systemic Lupus Erythematosus (SLE)
Nov 22, 2021 07:31AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All